細菌性肺炎市場- 世界の産業規模、シェア、動向、機会、予測、タイプ別、治療法別、投与経路別、流通チャネル別、地域別セグメント、競合、2020年～2030年

細菌性肺炎の世界市場規模は2024年に25億2,000万米ドルとなり、2030年までの予測期間のCAGRは7.18%で堅調な成長が予測されています。

細菌性肺炎の世界市場は、様々な細菌性病原体によって引き起こされ、流行し、生命を脅かす可能性のある呼吸器感染症である細菌性肺炎の予防、診断、治療に特化した重要なヘルスケア分野です。この市場は、細菌性肺炎の罹患率の上昇、医学研究と技術の進歩、世界の医療政策の進化など、いくつかの重要な要因によって形成されています。細菌性肺炎は依然として世界の健康上の重大な問題であり、あらゆる年齢層の個人に影響を及ぼしていますが、特に小児、高齢者、免疫系が低下している人に影響を及ぼしています。喫煙、慢性呼吸器疾患、環境汚染物質への曝露などの要因がその蔓延に寄与しています。市場は、効果的なワクチン、診断ツール、治療的介入を開発することにより、これらの課題に対処することに注力しています。

市場概要
予測期間	2026-2030
市場規模：2024年	25億2,000万米ドル
市場規模：2030年	37億9,000万米ドル
CAGR：2025年～2030年	7.18%
急成長セグメント	ワクチン
最大市場	北米

市場促進要因

細菌性肺炎の発生率の上昇

主な市場課題

抗生物質耐性

主要市場動向

ワクチン開発の進歩

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 世界の細菌性肺炎市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • タイプ別（市中肺炎（CAP）、院内肺炎（HAP））
  • 治療法（ワクチン、薬）別
  • 投与経路別（経口、皮下、その他）
  • 流通チャネル別（病院薬局、小売薬局、オンライン薬局）
  • 地域別
  • 企業別（2024）
• 市場マップ
  • タイプ別
  • 治療法別
  • 投与経路別
  • 流通チャネル別
  • 地域別

第5章 アジア太平洋地域の細菌性肺炎市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • タイプ別
  • 治療法別
  • 投与経路別
  • 流通チャネル別
  • 国別
• アジア太平洋地域：国別分析
  • 中国
  • インド
  • オーストラリア
  • 日本
  • 韓国

第6章 欧州の細菌性肺炎市場展望

• 市場規模・予測
• 市場シェア・予測
• 欧州：国別分析
  • フランス
  • ドイツ
  • スペイン
  • イタリア
  • 英国

第7章 北米の細菌性肺炎市場展望

• 市場規模・予測
• 市場シェア・予測
• 北米：国別分析
  • 米国
  • メキシコ
  • カナダ

第8章 南米の細菌性肺炎市場展望

• 市場規模・予測
• 市場シェア・予測
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第9章 中東・アフリカの細菌性肺炎市場展望

• 市場規模・予測
• 市場シェア・予測
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第10章 市場力学

• 促進要因
• 課題

第11章 市場動向と発展

• 最近の動向
• 製品上市
• 合併と買収

第12章 世界の細菌性肺炎市場：SWOT分析

第13章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第14章 競合情勢

• Innoviva Inc.
• Pfizer Inc.
• Merck & Co., Inc.
• Melinta Therapeutics LLC
• Evopoint Biosciences
• Aridis Pharmaceuticals Inc.
• Cumberland Pharmaceuticals Inc.
• Eagle Pharmaceuticals, Inc.
• Clarametyx Biosciences
• Basilea Pharmaceutica Ltd

第15章 戦略的提言

第16章 調査会社について・免責事項

Global Bacterial Pneumonia Market was valued at USD 2.52 billion in 2024 and is anticipated to project robust growth in the forecast period with a CAGR of 7.18% through 2030F. The global bacterial pneumonia market represents a critical healthcare sector dedicated to the prevention, diagnosis, and treatment of bacterial pneumonia, a prevalent and potentially life-threatening respiratory infection caused by various bacterial pathogens. This market is shaped by several key factors, including the rising incidence of bacterial pneumonia, advancements in medical research and technology, and evolving healthcare policies worldwide. Bacterial pneumonia remains a significant global health concern, affecting individuals of all ages, with a particular impact on children, the elderly, and individuals with compromised immune systems. Factors such as smoking, chronic respiratory conditions, and exposure to environmental pollutants contribute to its prevalence. The market focuses on addressing these challenges by developing effective vaccines, diagnostic tools, and therapeutic interventions.

Market Overview
Forecast Period	2026-2030
Market Size 2024	USD 2.52 Billion
Market Size 2030	USD 3.79 Billion
CAGR 2025-2030	7.18%
Fastest Growing Segment	Vaccines
Largest Market	North America

Key Market Drivers

Rising Incidence of Bacterial Pneumonia

The global bacterial pneumonia market is witnessing a significant boost due to the rising incidence of bacterial pneumonia worldwide. Bacterial pneumonia, a potentially life-threatening respiratory infection caused by various bacterial pathogens, has become increasingly prevalent in recent years, contributing to the growing demand for prevention, diagnosis, and treatment solutions within this healthcare sector. For instance, according to a 2024 National Center for Immunization and Respiratory Diseases article, Mycoplasma pneumoniae infections are rising, highlighting the need for increased awareness, timely diagnosis, and effective treatment to manage this growing public health concern.

Several factors contribute to the escalating incidence of bacterial pneumonia. One key factor is the aging global population, as elderly individuals and those with weakened immune systems are more susceptible to pneumonia. As the world's population continues to age, the number of people at risk of contracting bacterial pneumonia increases, leading to a greater need for healthcare services and products related to this infectious disease.

The lifestyle factors such as smoking, chronic respiratory conditions, and exposure to environmental pollutants contribute to the higher incidence of bacterial pneumonia. These risk factors are prevalent in many parts of the world, further fueling the demand for healthcare interventions. The ongoing COVID-19 pandemic has also had an indirect impact on the rising incidence of bacterial pneumonia. While COVID-19 itself is a viral respiratory infection, the pandemic has highlighted the importance of respiratory health and infection prevention. As a result, individuals are becoming more vigilant about their respiratory health, seeking medical attention for respiratory symptoms, and adopting preventive measures. This increased awareness and healthcare-seeking behavior have led to earlier diagnosis and treatment of bacterial pneumonia cases, further contributing to the market's growth.

The global bacterial pneumonia market is experiencing an upward trajectory driven by the escalating incidence of this infectious disease. Demographic factors, lifestyle choices, and the heightened awareness of respiratory health due to the COVID-19 pandemic all play pivotal roles in boosting the demand for bacterial pneumonia-related healthcare services and products.

Key Market Challenges

Antibiotic Resistance

Antibiotic resistance has emerged as a formidable challenge hindering the global bacterial pneumonia market, threatening the effectiveness of treatment and posing a significant public health concern. Bacterial pneumonia, a common and potentially life-threatening respiratory infection caused by various bacterial pathogens, relies heavily on antibiotics for treatment. However, the alarming rise of antibiotic-resistant strains of these bacteria is undermining the ability to combat this disease effectively.

The rise of antibiotic resistance in bacterial pneumonia is primarily attributed to the overuse and misuse of antibiotics. Antibiotics, once hailed as miracle drugs, have been prescribed excessively for respiratory infections, often when they are not necessary, contributing to the development of resistance. This overreliance on antibiotics has accelerated the evolution of bacterial pathogens, making them less responsive to conventional treatments.

One of the critical consequences of antibiotic resistance is the limited pool of effective antibiotics available for treating bacterial pneumonia. The bacteria responsible for this infection, such as Streptococcus pneumoniae and Haemophilus influenzae, have developed resistance to multiple antibiotic classes, leaving healthcare providers with fewer treatment options. Patients with antibiotic-resistant bacterial pneumonia may experience prolonged illness, increased hospitalizations, and higher mortality rates.

Key Market Trends

Advancements in Vaccine Development

Advancements in vaccine development have emerged as a significant driving force behind the growth of the global bacterial pneumonia market. Bacterial pneumonia, caused by various bacterial pathogens, has long been a major global health concern, particularly affecting vulnerable populations such as children and the elderly. Recent innovations in vaccine development are proving to be a game-changer in the fight against this life-threatening respiratory infection. One of the most noteworthy trends in the bacterial pneumonia market is the continuous improvement and expansion of vaccine options. Vaccines targeting key bacterial pathogens responsible for pneumonia, such as Streptococcus pneumoniae and Haemophilus influenzae type b, have undergone substantial advancements. These vaccines are designed to prevent infection, reduce the severity of pneumonia cases, and lower the risk of complications.

Childhood immunization programs have played a pivotal role in the adoption of these vaccines, with many countries incorporating them into their routine vaccination schedules. This widespread vaccination coverage has resulted in a decline in pneumonia-related hospitalizations and mortality among children, which is a significant public health achievement. Moreover, advancements in vaccine development have led to the creation of conjugate vaccines that offer broader protection against multiple bacterial strains. These vaccines have proven effective in reducing the incidence of bacterial pneumonia caused by various serotypes of the same bacterial species, contributing to improved outcomes and a decrease in antibiotic-resistant strains.

Key Market Players

• Innoviva Inc
• Pfizer Inc.
• Merck & Co., Inc.
• Melinta Therapeutics LLC
• Evopoint Biosciences
• Aridis Pharmaceuticals Inc.
• Cumberland Pharmaceuticals Inc.
• Eagle Pharmaceuticals, Inc.
• Clarametyx Biosciences
• Basilea Pharmaceutica Ltd

Report Scope:

In this report, the Global Bacterial Pneumonia Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Bacterial Pneumonia Market, By Type:

• Community-Acquired Pneumonia (CAP)
• Hospital-Acquired Pneumonia (HAP)

Bacterial Pneumonia Market, By Treatments:

• Vaccines
• Drugs

Bacterial Pneumonia Market, By Route of Administration:

• Oral
• Subcutaneous
• Other

Bacterial Pneumonia Market, By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Bacterial Pneumonia Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Bacterial Pneumonia Market.

Available Customizations:

Global Bacterial Pneumonia Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Global Bacterial Pneumonia Market Outlook

• 4.1. Market Size & Forecast
  • 4.1.1. By Value
• 4.2. Market Share & Forecast
  • 4.2.1. By Type (Community-Acquired Pneumonia (CAP), Hospital-Acquired Pneumonia (HAP))
  • 4.2.2. By Treatments (Vaccines, Drugs)
  • 4.2.3. By Route of Administration (Oral, Subcutaneous, Other)
  • 4.2.4. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
  • 4.2.5. By Region
  • 4.2.6. By Company (2024)
• 4.3. Market Map
  • 4.3.1. By Type
  • 4.3.2. By Treatments
  • 4.3.3. By Route of Administration
  • 4.3.4. By Distribution Channel
  • 4.3.5. By Region

5. Asia Pacific Bacterial Pneumonia Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type
  • 5.2.2. By Treatments
  • 5.2.3. By Route of Administration
  • 5.2.4. By Distribution Channel
  • 5.2.5. By Country
• 5.3. Asia Pacific: Country Analysis
  • 5.3.1. China Bacterial Pneumonia Market Outlook
    • 5.3.1.1. Market Size & Forecast
      • 5.3.1.1.1. By Value
    • 5.3.1.2. Market Share & Forecast
      • 5.3.1.2.1. By Type
      • 5.3.1.2.2. By Treatments
      • 5.3.1.2.3. By Route of Administration
      • 5.3.1.2.4. By Distribution Channel
  • 5.3.2. India Bacterial Pneumonia Market Outlook
    • 5.3.2.1. Market Size & Forecast
      • 5.3.2.1.1. By Value
    • 5.3.2.2. Market Share & Forecast
      • 5.3.2.2.1. By Type
      • 5.3.2.2.2. By Treatments
      • 5.3.2.2.3. By Route of Administration
      • 5.3.2.2.4. By Distribution Channel
  • 5.3.3. Australia Bacterial Pneumonia Market Outlook
    • 5.3.3.1. Market Size & Forecast
      • 5.3.3.1.1. By Value
    • 5.3.3.2. Market Share & Forecast
      • 5.3.3.2.1. By Type
      • 5.3.3.2.2. By Treatments
      • 5.3.3.2.3. By Route of Administration
      • 5.3.3.2.4. By Distribution Channel
  • 5.3.4. Japan Bacterial Pneumonia Market Outlook
    • 5.3.4.1. Market Size & Forecast
      • 5.3.4.1.1. By Value
    • 5.3.4.2. Market Share & Forecast
      • 5.3.4.2.1. By Type
      • 5.3.4.2.2. By Treatments
      • 5.3.4.2.3. By Route of Administration
      • 5.3.4.2.4. By Distribution Channel
  • 5.3.5. South Korea Bacterial Pneumonia Market Outlook
    • 5.3.5.1. Market Size & Forecast
      • 5.3.5.1.1. By Value
    • 5.3.5.2. Market Share & Forecast
      • 5.3.5.2.1. By Type
      • 5.3.5.2.2. By Treatments
      • 5.3.5.2.3. By Route of Administration
      • 5.3.5.2.4. By Distribution Channel

6. Europe Bacterial Pneumonia Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Treatments
  • 6.2.3. By Route of Administration
  • 6.2.4. By Distribution Channel
  • 6.2.5. By Country
• 6.3. Europe: Country Analysis
  • 6.3.1. France Bacterial Pneumonia Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Treatments
      • 6.3.1.2.3. By Route of Administration
      • 6.3.1.2.4. By Distribution Channel
  • 6.3.2. Germany Bacterial Pneumonia Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Treatments
      • 6.3.2.2.3. By Route of Administration
      • 6.3.2.2.4. By Distribution Channel
  • 6.3.3. Spain Bacterial Pneumonia Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Treatments
      • 6.3.3.2.3. By Route of Administration
      • 6.3.3.2.4. By Distribution Channel
  • 6.3.4. Italy Bacterial Pneumonia Market Outlook
    • 6.3.4.1. Market Size & Forecast
      • 6.3.4.1.1. By Value
    • 6.3.4.2. Market Share & Forecast
      • 6.3.4.2.1. By Type
      • 6.3.4.2.2. By Treatments
      • 6.3.4.2.3. By Route of Administration
      • 6.3.4.2.4. By Distribution Channel
  • 6.3.5. United Kingdom Bacterial Pneumonia Market Outlook
    • 6.3.5.1. Market Size & Forecast
      • 6.3.5.1.1. By Value
    • 6.3.5.2. Market Share & Forecast
      • 6.3.5.2.1. By Type
      • 6.3.5.2.2. By Treatments
      • 6.3.5.2.3. By Route of Administration
      • 6.3.5.2.4. By Distribution Channel

7. North America Bacterial Pneumonia Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Treatments
  • 7.2.3. By Distribution Channel
  • 7.2.4. By Route of Administration
  • 7.2.5. By Country
• 7.3. North America: Country Analysis
  • 7.3.1. United States Bacterial Pneumonia Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Treatments
      • 7.3.1.2.3. By Route of Administration
      • 7.3.1.2.4. By Distribution Channel
  • 7.3.2. Mexico Bacterial Pneumonia Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Treatments
      • 7.3.2.2.3. By Route of Administration
      • 7.3.2.2.4. By Distribution Channel
  • 7.3.3. Canada Bacterial Pneumonia Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Treatments
      • 7.3.3.2.3. By Route of Administration
      • 7.3.3.2.4. By Distribution Channel

8. South America Bacterial Pneumonia Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Treatments
  • 8.2.3. By Distribution Channel
  • 8.2.4. By Route of Administration
  • 8.2.5. By Country
• 8.3. South America: Country Analysis
  • 8.3.1. Brazil Bacterial Pneumonia Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Treatments
      • 8.3.1.2.3. By Route of Administration
      • 8.3.1.2.4. By Distribution Channel
  • 8.3.2. Argentina Bacterial Pneumonia Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Treatments
      • 8.3.2.2.3. By Route of Administration
      • 8.3.2.2.4. By Distribution Channel
  • 8.3.3. Colombia Bacterial Pneumonia Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Treatments
      • 8.3.3.2.3. By Route of Administration
      • 8.3.3.2.4. By Distribution Channel

9. Middle East and Africa Bacterial Pneumonia Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Drug Type
  • 9.2.3. By Route of Administration
  • 9.2.4. By Distribution Channel
  • 9.2.5. By Country
• 9.3. MEA: Country Analysis
  • 9.3.1. South Africa Bacterial Pneumonia Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Treatments
      • 9.3.1.2.3. By Route of Administration
      • 9.3.1.2.4. By Distribution Channel
  • 9.3.2. Saudi Arabia Bacterial Pneumonia Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Drug Type
      • 9.3.2.2.3. By Route of Administration
      • 9.3.2.2.4. By Distribution Channel
  • 9.3.3. UAE Bacterial Pneumonia Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Treatments
      • 9.3.3.2.3. By Route of Administration
      • 9.3.3.2.4. By Distribution Channel

10. Market Dynamics

• 10.1. Drivers
• 10.2. Challenges

11. Market Trends & Developments

• 11.1. Recent Developments
• 11.2. Product Launches
• 11.3. Mergers & Acquisitions

12. Global Bacterial Pneumonia Market: SWOT Analysis

13. Porter's Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Product

14. Competitive Landscape

• 14.1. Innoviva Inc.
  • 14.1.1. Business Overview
  • 14.1.2. Company Snapshot
  • 14.1.3. Products & Services
  • 14.1.4. Current Capacity Analysis
  • 14.1.5. Financials (In case of listed)
  • 14.1.6. Recent Developments
  • 14.1.7. SWOT Analysis
• 14.2. Pfizer Inc.
• 14.3. Merck & Co., Inc.
• 14.4. Melinta Therapeutics LLC
• 14.5. Evopoint Biosciences
• 14.6. Aridis Pharmaceuticals Inc.
• 14.7. Cumberland Pharmaceuticals Inc.
• 14.8. Eagle Pharmaceuticals, Inc.
• 14.9. Clarametyx Biosciences
• 14.10. Basilea Pharmaceutica Ltd

15. Strategic Recommendations

16. About Us & Disclaimer